<DOC>
	<DOCNO>NCT00205504</DOCNO>
	<brief_summary>Oral contraceptive ( OCs ) widely use method reversible birth control . However , long-term cardiovascular safety widely use low-dose OCs ( ethinyl-estradiol &lt; 50 mcg ) still debate . Although cardiovascular event rare young woman whether use OCs , risk myocardial infarction ischemic stroke increase among user OCs conventional cardiovascular risk factor use tobacco , diabetes hypercholesterolemia . However , risk cardiovascular event OC user emerge cardiovascular risk factor ( obesity metabolic syndrome ) investigate . Recently , metabolic syndrome link risk cardiovascular disease . The syndrome clustering risk factor single individual , underlying cause may insulin resistance . Whether metabolic syndrome predict high cardiovascular risk OC user study . This critical problem metabolic syndrome prevalent 24 % adult . Until cardiovascular risk user OC clearly define , appropriate use OC least harm would possible . The investigator 's long-term goal understand best way prevent treat cardiovascular disease woman . The objective particular project obtain pilot data extent metabolic syndrome obesity affect glucose metabolism cardiovascular risk woman take OCs . The researcher hypothesize woman metabolic syndrome obese woman worsen glucose metabolism elevate cardiovascular risk associate OC use , compare normal weight woman without metabolic syndrome . Results study clarify risk factor cardiovascular event woman take OCs , serve pilot data National Institutes Health ( NIH ) proposal . Once cardiovascular risk factor OC user understand , clinician make good inform decision contraceptive choice patient .</brief_summary>
	<brief_title>Oral Contraceptives Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<criteria>1 . Acceptable health base interview , medical history , physical examination , laboratory test ( comprehensive metabolic panel SMA20 , complete blood count CBC ) ; 2 . Have take oral contraceptive ( OCs ) past 3 month ; 3 . Ability comply requirement study ; 4 . Ability willingness provide sign , witness informed consent . In addition , woman metabolic syndrome must meet National Cholesterol Education Program ( NCEP ) define criterion metabolic syndrome , , least 3 5 factor : 1. increase waist circumference &gt; 35 inch , 2. hypertriglyceridemia ≥ 150 mg/dL , 3. low highdensity lipoprotein ( HDL ) cholesterol &lt; 50 mg/dL woman , 4. hypertension ( ≥ 130/≥ 85 mmHg ) , 5. fast glucose ≥ 100 mg/dL . Obese woman without metabolic syndrome Body Mass Index ( BMI ) &gt; 30 kg/m2 lean woman Body Mass Index BMI &lt; 25 kg/m2 . 1 . Diabetes mellitus fast glucose 2hour oral glucose tolerance test ( OGTT ) ; 2 . Clinically significant pulmonary , cardiac ( include limit ischemic heart disease , stable/unstable angina , congestive heart failure ) , renal , hepatic , cholestatic , neurologic , psychiatric , infectious , malignant disease ( melanoma skin cancer ) ; 3 . History thromboembolism , myocardial infarction , cerebrovascular accident , vascular disease , know coagulopathy , prolonged immobilization , recent major surgery ( within past 6 month ) ; 4 . Systolic blood pressure great 160 mmHg diastolic blood pressure great 100 mmHg ( mild hypertension exclusion criterion ) ; 5 . History breast cancer , migraine headache , age ≥ 35 year smoker ≥ 20 cigarettes/day ; 6 . Use metformin , thiazolidinediones , antihyperlipidemic drug , antihypertensive drug , glucocorticoid , antiandrogens ( spironolactone , flutamide , etc . ) within 3 month ; 7 . Documented suspected illicit drug abuse alcoholism within one year ; 8 . Ingestion investigational drug within 3 month prior study onset ; 9 . Pregnancy lactation ( ≤ 6 week postpartum ) ; 10 . Hematocrit &lt; 33g/dL . These exclusion criterion base study requirement also go beyond guideline OC use publish World Health Organization .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Inflammatory marker , oral contraception , obesity , metabolic syndrome X</keyword>
</DOC>